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Abstract
Cancer stem cells, initiating and sustaining the tumor process, have been isolated in human and murine breast
cancer using different cell markers. In the present study, we aimed to evaluate the presence and characteristics
of stem/tumor–initiating cells in the model of the mouse mammary neoplasia driven by the activated form of rat
Her-2/neu oncogene (BALB-neuT mice). For this purpose, we generated tumor spheres from primary spontaneous
BALB-neuT tumors. Tumor sphere cultures were characterized for clonogenicity, self-renewal, and ability to differ-
entiate in epithelial/myoepithelial cells of the mammary gland expressing basal and luminal cytokeratins and alpha-
smooth muscle actin. In addition, tumor spheres were more resistant to doxorubicin compared with parental tumor
cells. In the attempt to identify a selectedmarker for the sphere-generating cells, we found that Sca-1+ cells, present
in tumors or enriched inmammospheres, and not CD24+ or CD29+ cells, were responsible for the sphere generation
in vitro. Moreover, cells from the tumor spheres showed an increased tumor-generating ability in respect to the
epithelial tumor cells. Sca-1+ sorted cells or clonal mammospheres derived from a Sca-1+ cell showed a superim-
posable tumor-initiating ability. The data of the present study indicate that a Sca-1+ population derived from mam-
mary BALB-neuT tumors is responsible for sphere generation in culture and for initiating tumors in vivo.
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Introduction
Growing evidences support the hypothesis that the tumorigenic pro-
cess is sustained by a small population of cells, named tumor-initiating
cells or tumor stem cells [1,2]. Tumor-initiating cells are characterized
by their ability to form new serially transplantable tumors in mice and
to display stem/progenitor cell properties such as competence for self-
renewal and capacity to reestablish tumor heterogeneity [3,4]. Tumor
stem cells have been identified in several human solid tumors and iso-
lated by the selection for specific different markers [5–11]. In human
breast carcinoma, the tumor-initiating cells have been identified by Al
Hajj et al. [12] as a rare population of CD44+/CD24−/low/epithelial–
specific antigen+ cells. Furthermore, tumor-initiating cells were also
isolated for the ability to grow as nonadherent spheres. This property
was first described for neuronal progenitors [13] and then extended
to progenitors of the mammary gland [14], to human breast cell lines
[15], and to human and murine breast carcinomas [16–18]. In this
condition of culture, tumor-initiating cells can be expanded and main-
tained in an undifferentiated state [16].
In mouse mammary glands, transgenic activation of different onco-
genic pathways generates tumors with particular histopathologic fea-
tures, resembling the human specific types of breast carcinomas [19].
In particular, the transgenic activation of Wnt induces tumors of epi-
thelial andmyoepithelial origin, suggesting that tumors may arise from
multilineage progenitor cells. In contrast, the activation of Her-2/neu
Abbreviations: neu, Her-2/neu oncogene; MMTV, mammary tumor virus promoter;
bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; α-SMA, α-smooth
muscle actin; CK, cytokeratin
Address all correspondence to: Prof. Benedetta Bussolati, MD, Dipartimento di Medi-
cina Interna, Corso Dogliotti 14, 10126, Torino, Italy.
E-mail: benedetta.bussolati@unito.it
1This work was supported by the Associazione Italiana per la Ricerca sul Cancro, by
the Italian Ministry of University and Research COFIN06 and ex60%, by Progetti
Finalizzati Regione Piemonte and Oncoprost, and by Progetto S. Paolo Oncologia.
2These authors equally contributed to this work.
Received 4 August 2008; Revised 12 September 2008; Accepted 12 September 2008
Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00
DOI 10.1593/neo.08902
www.neoplasia.com
Volume 10 Number 12 December 2008 pp. 1433–1443 1433
oncogene (neu) generates tumors with cells more strictly committed
to the luminal fate [20,21], suggesting the involvement of luminal-
restricted progenitors [22]. The presence and characteristics of stem/
tumor–initiating cells in the model of the mouse mammary neoplasia
driven by the activated transforming form of rat neu oncogene (BALB-
neuTmice) are still unknown.
This model is characterized by the overexpression of the activated
rat neu oncogene under the control of the mouse mammary tumor vi-
rus promoter (MMTV) [23]. The transgene encodes a 185-kDa trans-
membrane tyrosine kinase receptor, which is prevalently expressed in
mammary glands of these mice. At 3 weeks of age, female BALB-neuT
mice start a process of rapid development of tumors involving all the
mammary glands.
Tumor progression in BALB-neuTmice is closely similar to that of
human carcinoma, progressing from atypical hyperplasia to invasive
tumor with short latency [24]. Moreover, in human breast carcinoma,
it has been recently described that Her-2 overexpression increased the
number of stem/progenitor cells [25]. It is therefore of interest to iso-
late the stem cell population in a model of Her-2 activation and to
identify a marker for their selection. In the present study, we aimed
to evaluate whether there is a population of stem/tumor-initiating
cells in the BALB-neuT tumor model. For this purpose, we generated
tumor spheres from primary spontaneous tumors. Tumor spheres cul-
tures were characterized for the self-renewal, differentiative ability and
for their tumorigenic potential. In addition, we evaluated the chemo-
resistance of the tumor sphere to doxorubicin compared with that of
parental tumor cells. Finally, we investigated whether tumor sphere–
generating cells expressed selective stem cell markers that allow the
identification of this population. In particular, we evaluated whether
cells expressing Sca-1 were enriched in tumor spheres and were respon-
sible for the sphere generation in vitro and for initiating tumors in vivo.
Materials and Methods
Isolation and In Vitro Expansion of Tumor Sphere–Forming
Cells from Mammary Tumor Specimens
Primary mammary tumor specimens were obtained from sponta-
neous carcinomas developed in BALB-neuT female mice carrying the
activated form of rat neu oncogene [23,24]. The histologic assess-
ment showed a human-like lobular carcinoma of alveolar type. Tumor
specimens (each time 3-6 spontaneous tumors from the same mouse;
n = 15) were finely minced with scissors and then digested by incu-
bation for 30 minutes at 37°C in DMEM containing collagenase II
(Sigma Chemical Company, St. Louis, MO). After washing in medium
plus 10% FCS (GIBCO, Grand Island, NY), the cell suspension was
forced through a 40-μm pore filter (Becton Dickinson, San Jose, CA)
to separate the cell components from stroma and aggregates. Single
cells were plated at 1000 cells/ml in serum-free DMEM-F12 (Cambrex
BioScience, Venviers, Belgium), supplemented with 10 ng/ml basic
fibroblast growth factor (bFGF), 20 ng/ml epidermal growth factor
(EGF), 5 μg/ml insulin, and 0.4% bovine serum albumin (all from
Sigma), as described [16]. Nonadherent spherical clusters of cells,
named tumor spheres, appeared at day 7. At day 10, tumor spheres were
collected on the bottom of a conical tube by spontaneous precipitation
(10 minutes at room temperature) to remove nonliving cells. After 3 to
5 days, tumor spheres were collected and disaggregated through enzy-
matic and mechanical dissociation using trypsin and pipetting, respec-
tively. Recovered cells were expanded at 1000 cells/ml in the serum-free
medium described above, and the process was repeated every 10 to
12 days [17].
The single tumor cell suspension (80,000-100,000 cells/cm2) was
also plated in RPMI (Sigma) supplemented with 10% of FCS to ob-
tain adherent tumor epithelial cells.
Isolation of Selected Cell Populations from Spheres and Tumors
Subpopulation of cells were isolated from primary mammary tu-
mor specimens and from tumor spheres in culture using antibodies
(Abs) coupled to magnetic beads, by magnetic cell sorting using the
magnetic-activated cells sorting (MACS) system (Miltenyi Biotec,
Auburn, CA). The cells suspension was incubated with the following
Abs: anti–Sca-1 coupled to beads (Miltenyi Biotec), anti-CD24 and
rat anti-CD29 (PharMingen, BD Biosciences, Franklin Lakes, NJ).
For CD24 and CD29, a second step reagent was needed: cells were
stained by the addition of polyclonal goat antirat immunoglobulins
conjugated to magnetic beads (Myltenyi Biotec). Cells were separated
on a magnetic stainless steel wool column (Myltenyi Biotec) according
to the manufacturer’s recommendations. Purity was assessed by cyto-
fluorimetric analysis, and it was >95% in all preparations.Moreover, to
test the importance of Sca-1 molecule in respect to CD24, by cell sort-
ing, we fractioned primary mammary tumor cells into Sca-1+/CD24+
and Sca-1+/CD24− cells. Cells were labeled with the anti-CD24 Ab
FITC Ab (PharMingen) and with anti–Sca-1 PE Ab.
Clonal Sphere Formation Assay
Primary tumor spheres were dissociated as described above, and
100 cells were plated in a 96-well culture plate to obtain a single cell
per well in 150 μl of growth medium; 25 μl of medium per well was
added every 5 days [17]. The number of clonal tumor spheres for each
96-well culture plate was evaluated after 14 days of culture. This pro-
cedure was repeated for secondary and tertiary clonal spheres and for
Sca-1+ cells recovered from spheres or tumors.
Tumor Sphere Generation Assay
To investigate the number of single cells able to generate a new
sphere, dissociated primary tumor spheres were cultured at the density
of 1000 cells/ml; 4 ml/well of the cell suspension was placed in a six-
well dish to obtain new spheres. The total number of tumor spheres for
each well was counted after 14 days of culture. This procedure was
repeated for three passages in culture (each passage, n = 10) [18,26].
The tumor sphere–generating ability was also evaluated for specific
subpopulations of cells from tumors and spheres in culture, selected
by immunomagnetic cell sorting as described above. The subpopu-
lations were CD24- (n = 6), CD29- (n = 6), and Sca-1– (n = 11) pos-
itive and negative cells. We also tested the ability to generate sphere of
Sca-1+/CD24+ and Sca-1+/CD24− cells (n = 3); the two populations
were cultured at the density of 1000 cells/ml, and the total number of
tumor spheres for each well was counted after 7 days of culture.
Immunofluorescence
Cytofluorimetric analysis was performed using the following Abs:
purified rat anti-CD44, rat anti-CD24, rat anti-CD29, and FITC-
conjugated anti–Sca-1 (PharMingen). Isotype-matched and PE-
conjugated control rat IgG were fromCaltag Laboratories (Burlingame,
CA). Cells were incubated for 30 minutes at 4°C with the appropriate
Ab or with the irrelevant control in PBS containing 2% heat-inactivated
human serum. Where needed a second step reagent, cells were stained
by the addition of conjugated polyclonal goat antirat immunoglobulins/
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PE (Caltag Laboratories) and incubated for a further 30minutes at 4°C.
Cells were analyzed on a FACScan (Becton Dickinson). A total of
10,000 cells were analyzed in each sample.
For confocal microscopy analysis, indirect immunofluorescence was
performed on tumor sphere–derived cells on cytospin preparation of
a single cell suspension. Briefly, tumor spheres were dissociated using
the nonenzymatic cell solution (Sigma). The cell suspension was cen-
trifuged by cytospin on microscope slides and fixed by immersion on
precooled acetone for 20 minutes at −20°C. For cells grown in adhe-
sion (epithelial cells or spheres cultured in adhesion’s condition), indi-
rect immunofluorescence was performed on cells cultured on chamber
slides (Nunc, Rochester, NY). Cells were fixed in 3.5% paraformal-
dehyde containing 2% sucrose and, when needed, permeabilized with
Hepes–TritonX-100 0.1% for 10minutes at 4°C [17]. Anti–cytokeratin
14 (CK14), anti-CK18, or anti-CK19 Abs (Santa Cruz Biotechnology,
Santa Cruz, CA), anti α-smooth muscle actin (α-SMA) monoclonal Ab
(Dako, Copenhagen, Denmark), and anti–Oct-4 Ab (Abcam, Cambridge,
UK) were used.
Alexa Fluor 488 or Texas Red–conjugated antirabbit, antigoat, antirat,
and antimouse IgG (all fromMolecular Probes, Leiden, theNetherlands)
were used as secondary Abs. Confocal microscopy analysis was per-
formed using a Zeiss LSM 5 Pascal model confocal microscope (Carl
Zeiss International,Oberkochen,Germany).Hoechst 33258dye (Sigma)
was added for nuclear staining.
In Vitro Cell Differentiation
To evaluate the differentiative ability of cells growing as spheres,
tumor spheres obtained from primary tumors were expanded, dissoci-
ated, and plated in the differentiative epithelial medium RPMI, in the
presence of serum (10%), without the addition of growth factors. After
2 weeks of culture, we analyzed the expression of basal and luminal
cytokeratins and myoepithelial markers as described above.
Drug Resistance Assay
The sensitivity of tumor spheres to doxorubicin was compared
with that of tumor epithelial cells or of tumor spheres in differentiative
condition. Tumor spheres, dissociated by trypsin as single cells, tumor
epithelial cells, and differentiated sphere-derived cells were seeded in
RPMI without serum (3000 cells per well). Each type of cell was stim-
ulated for 72 hours with different doses of doxorubicin (250, 500,
1000 ng/ml). Apoptosis was evaluated by TUNEL assay (ApopTag
Oncor, Gaithersburg, MD). For cells growing in suspension as spheres,
we followed the manufacturer’s instruction for cell suspension, and at
the end, we centrifuged the plate at 5000 rpm for 10minutes to promote
cell adhesion.
Moreover, to determine the effect of drug stimulation on sphere
generation, dissociated tumor spheres were plated at the density of
1000 cells/ml as described previously in the presence of 500 ng/ml
of doxorubicin. The total number of spheres was counted after 6 days
of culture.
In Vivo Tumorigenesis Assay
Tumor epithelial cells, tumor sphere-derived cells, or whole tumor
spheres were implanted subcutaneously in the left and right flanks
of syngeneic BALB/c female mice using increasing cell number (1, 5,
and 50 spheres and 200, 1000, and 10,000 cells). Cells or spheres were
Figure 1. Tumor sphere generation and self-renewal. Tumor spheres were obtained by culture of dissociated cells from mouse mam-
mary carcinomas of BALB-neuT mice in tumor sphere medium containing EGF and bFGF. (A) Representative micrographs showing the
morphology of tumor spheres within time. After 1 to 2 weeks, tumor spheres resembling a golf ball were observed; after 3 weeks, in the
absence of trypsin treatment, tumor spheres showed a dark center owing to cell death. Original magnification, ×200. (B) Evaluation of
the number of single cells able to generate spheres. Cells were plated at the density of 1000 cells/ml. The number of sphere forming
cells was higher in the disaggregated spheres in culture (secondary or tertiary) in respect to the primary tumor cell population. Data are
the mean ± SD of nine different experiments. Analysis of variance with Dunnett’s multicomparison test was performed on secondary
and tertiary spheres versus tumor neuT: *P < .01. (C) Tumor sphere clone formation analysis in secondary and tertiary passages in
culture. The number of tumor sphere clones per 100 cells was evaluated. Data are the mean ± SD of 12 different experiments.
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diluted in 150 μl of PBS and injected at the first passage of culture. The
growth of the tumor was monitored every week, by a caliper. We ex-
pressed the growth asmean of tumor diameter. After 9 to 12weeks,mice
were killed, and tumors were recovered and processed for histology or
cell culture. For serial transplant experiments, tumors were digested in
collagenase II, and the recovered cells were processed to culture in tumor
sphere and epithelial conditions as described above. Mice were killed
according to the ethics protocols.
Immunohistochemistry
Sections from paraffin-embedded blocks of tumors obtained in
BALB/c mice were collected onto poly-L-lysine–coated slides and
stained using the following Abs: goat anti-CK14, rabbit anti-CK18,
or rabbit anti-neu (all from Santa Cruz Biotechnology). Endogenous
peroxidase activity was blocked with 6% H2O2 for 8 minutes at room
temperature. Primary Abs were applied to slides overnight or for
3 hours at 4°C, followed by incubation with horseradish peroxidase–
labeled antirabbit or antigoat Envision polymers (Dako) for 1 hour.
The reaction product was developed using 3,3-diaminobenzidine.
Omission of the primary Ab or substitution with an unrelated rabbit
serum served as negative control.
Statistical Analyses
Data are presented as means ± SD. Statistical and significant differ-
ences were determined using analysis of variance with the Newman-
Keuls’ or Dunnett’s multicomparison tests when appropriate. Differences
in tumor takes were evaluated with the χ 2 contingency test. Differ-
ences in tumor’s growth and latency time were determined by Stu-
dent’s t test. A P value of < .05 was considered significant.
Results
Tumor Sphere Generation from Mammary Tumors of
BALB-neuT Mice
Mouse mammary tumor stem cells were obtained from mouse
mammary carcinomas driven by the activated rat neu oncogene [23],
exploiting their ability to grow in nonadherent conditions as spheres
Figure 2. Tumor sphere characterization by cytofluorimetric analysis. Representative analysis of tumor sphere–derived cells (A) and
tumor epithelial cells cultured in adhesion (B) showing the expression of Sca-1, CD24, CD44, and CD29. Sca-1+ cells were enriched
in spheres, whereas the number of CD44- and CD29-expressing cells was decreased. Fifteen different experiments were performed
with similar results.
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[16]. Tumor spheres were obtained by culturing enzymatically dis-
sociated single-cell suspension plated at 1000 cells/ml in serum-free
medium supplemented with EGF, bFGF, and insulin to promote the
formation of spheres. After 2 weeks of culture, spheres resembling a
golf ball–like structure were obtained, as described by Liu et al.
[18]. The spheres were hollow inside in the first days; thereafter, they
were filled of living cells that died if the sphere was not trypsinized at
the end of the third week (Figure 1A). Primary tumor spheres, enzy-
matically digested after 10 to 14 days and replated as single cell sus-
pension, generated second passage tumor spheres. This procedure
was performed for more than 30 times in culture, without any differ-
ence in the sphere formation. To investigate the presence of tumor
sphere–generating cells in the tumor spheres, single living cells were
plated at the density of 1000 cells/ml, and the formed spheres were
counted after 2 weeks.Whereas in the hole primary tumor population,
the number of sphere-forming cells was 1/206 ± 12 (mean ± SD), in the
disaggregated spheres in culture (secondary or tertiary), the number of
sphere-forming cells was significantly increased (1/38 ± 4; mean ± SD;
P < .01; Figure 1B).
In addition, the tumor spheres were cloned by limiting dilution of
dissociated cells, by plating one single cell per well into 96-well culture
plates. Clonal, nonadherent secondary tumor spheres formed, which
in turn gave rise to tertiary tumor sphere clones, indicating the pres-
ence of self-renewing cells (Figure 1C ).
These data indicate that a population of sphere-generating cells with
self-renewal ability is present in mammary carcinomas of BALB-neuT
mice, and it is enriched in the spheres.
In parallel, we isolated epithelial cells from the same BALB-neuT
mammary tumors, plating the tumor single cell suspension in culture
withRPMI supplementedwith 10%of serum.Wemaintained this popu-
lation for several passages in culture for comparison with cells growing
as spheres.
Sphere Characterization
The expression of stem and differentiative markers was assessed on
sphere-forming cells and compared to the entire epithelial cell popu-
lation derived from the same mammary tumors. Approximately 20%
of cells of the tumor spheres expressed Sca-1 (Figure 2A). Sca-1+ popu-
lation was enriched in spheres compared to that of the entire cell popu-
lation fromBALB-neuT tumors that was around 6% to 7% (not shown).
On the contrary, Sca-1 expression was undetectable in tumor epithelial
cells cultured in adhesion (Figure 2B). In addition, the percentage of cells
Figure 3. Expression of cytokeratins and stem cells markers on tumor spheres and tumor epithelial cells. (A) Representative micro-
graphs showing the immunofluorescence staining by sphere-derived cells of CK14, CK18, and CK19 by confocal microscopy. Moreover,
the punctuate nuclear staining of Oct-4 was observed in some cells. Negative staining was observed for α-SMA. (B) Representative
micrographs showing the expression of CK18 and not CK14 or Oct-4 by adherent epithelial tumor cells by confocal microscopy. Original
magnification, ×650. Nuclei were counterstained with Hoechst dye.
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expressing CD44 and CD29 was decreased in spheres (Figure 2A) com-
pared with epithelial cells (Figure 2B). Almost all of the cells in both
spheres and adherent tumor epithelial cells were positive for CD24
(Figure 2, A and B). Cells of the tumor spheres also expressed differen-
tiation markers of the glandular epithelium such as CK14, CK18, and
CK19 (Figure 3A). In contrast, adherent tumor epithelial cells only ex-
pressed the luminal type CK18 (Figure 3B) as did the tumor of origin
[19,20,27]. Moreover, some cells of tumor spheres, but no cell from
tumor epithelium, showed a nuclear staining for the stem cell marker
Oct-4 (Figure 3).
We evaluated the ability of sphere-derived cells to differentiate, plat-
ing single cells in the presence of serum without growth factor sup-
plementation, as described by Ponti et al. [16]. All plated cells grew in
adherent conditions, maintained cytokeratin expression, and acquired
markers associated to the myoepithelial line such as α-SMA (Figure 4).
Moreover, differentiated cells lost the expression of Oct-4 (not shown).
No expression of CK14 and α-SMA was observed in tumor epithelial
cells in culture in the same condition. Altogether, these data suggest
the presence, in the spheres, of a population with different epithelial
lineage capacity able to express basal and luminal cytokeratins and
myoepithelial markers.
Drug Resistance of Sphere-Forming Cells
We compared the response to treatment with the cytotoxic drug doxo-
rubicin in single cells from tumor spheres, in epithelial-differentiated
cells cultured in adhesion, and in the primary tumor epithelial cells.
Epithelial-differentiated cells cultured in adhesion and primary tumor
cells underwent apoptosis after 72 hours of treatment with doxo-
rubicin in a dose-dependent manner (Figure 5A). On the contrary,
cells from tumor spheres neither showed apoptosis nor significantly
decreased sphere-generating ability when treated with doxorubicin
(Figure 5B). These data indicate that tumor sphere–derived cells are
chemoresistant to doxorubicin.
Sphere Generation by Sca-1–Positive Cells
To determine whether the potential of generating spheres resides
in a specific subpopulation of cells, we fractioned by immunomagnetic
cell sorting CD24-, CD29-, and Sca-1–positive versus –negative cells
both from primary tumors and from spheres in culture. These markers
were previously shown to be important for the selection of normal and
cancer stem cells [18,28–32]. Every single population was plated
in sphere-generating condition and compared with the negative popu-
lation for the sphere-generating ability. Figure 6A shows the purity of
the sorted populations. Only the Sca-1+ cell population was enriched
in sphere-generating cells in respect to the total population, to the
CD29- and CD24-positive and -negative cells or to the Sca-1-negative
cells (Figure 6, B and C ). To assess the possible role of CD24 expres-
sion in the characterization of Sca-1+ sphere-initiating cells, we further
fractioned Sca-1+ cells into Sca-1+/CD24+ and Sca-1+/CD24− cells.
Figure 4. Expression of differentiation markers of the glandular
epithelium by tumor spheres cultured in epithelial differentiative
medium with serum. Representative micrographs showing by im-
munofluorescence the positivity for CK18, CK14, and CK19 (A,
B, C) and the acquirement of the myoepithelial marker α-SMA
(D). Original magnification, ×650. Nuclei were counterstained with
Hoechst dye.
Figure 5. Drug resistance of sphere-forming cells. (A) Sphere-
derived cells (white columns), epithelial tumor cells (black columns),
and spheres cultured in differentiative condition (gray columns)
were treated with different dose of doxorubicin for 72 hours; apop-
tosis was evaluated by TUNEL assay. A significant resistance to
doxorubicin was observed in sphere-derived cells. Analysis of vari-
ance with Dunnett’s multicomparison test was performed among
spheres-derived cells and epithelial tumor or differentiated cells:
*P < .01. (B) Sphere generation from single cells in presence or
not of doxorubicin (500 ng/ml). The number did not significantly
decrease. Data are the mean ± SD of three different experiments
performed in quadruplicate.
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No difference in sphere-generating ability was observed between
the two populations (Sca-1+/CD24+: 24 ± 2; Sca-1+/CD24−: 20 ± 3,
n = 3) indicating that CD24 expression was not relevant in our model.
The increased ability of Sca-1+ cells to form spheres was observed
when Sca-1+ cells were freshly isolated either from tumors or from cul-
tured spheres. In the latter condition, the number of spheres generated
was higher (Figure 6C ), possibly owing to the enrichment of sphere-
generating cells within tumor spheres.
Spheres obtained from Sca-1+ cells showed the same morphology,
clonogenic ability, and marker expression of the spheres obtained
from the total tumor population (not shown). Sca-1 expression in tumor
spheres derived from Sca-1+ cells was still present in 20 ± 4%of cells (n =
9 experiments).
In Vivo Tumorigenesis of Spheres
To determine whether spheres differ in their tumorigenic potential
from tumor epithelial cells growing as monolayer, sphere-forming cells,
either as whole spheres or as single cells, and tumor-derived cells were
implanted subcutaneously in the left and right flanks of syngeneic
BALB/c female mice, using increasing cell number (1, 5, and 50 spheres
Figure 6. Sphere generation by Sca-1–positive cells. CD24-, CD29-, and Sca-1–positive and –negative cells were isolated, by immuno-
magnetic cell sorting from primary tumors and from spheres in culture. (A) Representative cytofluorimetric analysis showing the purity
of the sorted populations. (B and C) CD24-, CD29-, and Sca-1–positive and –negative cells, selected from primary tumors (B) and from
spheres in culture (C) were plated at the density of 1000 cells/ml to evaluate the number of spheres obtained from single cells. Only the
Sca-1+ cell population was enriched in sphere generating cells. Analysis of variance with Newman-Keuls’ multicomparison test was
performed among Sca-1 and unselected or selected with other markers, *P < .01; and among the positive and the negative fraction,
#P < .01. Data are the mean ± SD of 10 different experiments.
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and 200, 1000, and 10,000 sphere-derived or epithelial cells). We in-
jected cells and spheres at the first passage of culture.
As shown in Table 1, one tumor sphere was able to generate an epi-
thelial tumor in 6 weeks, resembling the tumor of origin, with the inci-
dence of 50%, that increasedwhen five spheres were injected.Moreover,
cells from a disaggregated sphere (200 cells) also generated tumors with
an incidence comparable to that obtained by the injection of a whole
sphere. A comparable number of tumor epithelial cells did not generate
tumors. Moreover, a significantly higher tumor incidence was observed
using 5 tumor spheres or 1000 tumor sphere–derived cells in compari-
son with 1000 tumor epithelial cells (Table 1). In this condition, the
tumor growthwas also significantly higher (Figure 7A). The latency time
from challenge until growth of a 4-mm-diameter tumor was statistically
different comparing 200 and 1000 sphere–derived cell, or the corre-
sponding 1 and 5 spheres, with 200 and 1000 tumor epithelial cells
(P < .01 and P < .05, respectively; Figure 7A).
To evaluate the ability to initiate tumors in serial passages, we recov-
ered from primary tumors the cells that we cultured both as spheres
Figure 7. Tumorigenesis assay. (A) Spheres, sphere-derived cells, and epithelial tumor cells growing as monolayer were subcutaneously
injected at the first passage of culture in syngeneic BALB/c female mice, in increasing cell number (1, 5, and 50 spheres and 200, 1000,
and 10,000 sphere-derived or epithelial cells). The tumor growth was monitored every week by a caliper, and the tumor diameter was
measured and expressed as the tumor mean diameter. Each point represents the mean ± SD of mice developing tumors (Table 1).
Student’s t test was performed: *P < .01, #P < .05. The latency time from challenge until growth of 4-mm-diameter tumor (dot red line)
was statistically different comparing tumors from 1 sphere or 200 sphere-derived cells with 200 tumor epithelial cells (no tumor) and
comparing tumors from 5 spheres or 1000 sphere-derived cells with 1000 tumor epithelial cells (days: 24 ± 3, 26 ± 3, and 43 ± 4,
respectively). Student’s t test was performed: P < .05. (B) Representative micrographs showing that the tumors generated by epithelial
tumor cells in culture or spheres resembled the spontaneous tumors of BALB-neuT mice. By immunohistochemistry, the sphere-derived
tumors (lower panels) showed a luminal phenotype characterized by the expression of CK18 and of the neu transgene, but not of CK14. H&E
indicates hematoxylin and eosin. Original magnification, ×200.
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and as adherent epithelial cells and we performed serial transplants
(Table 1). The capacity of single spheres to generate tumors was main-
tained in the secondary and tertiary passages. Moreover, tumor inci-
dence was increased within passages.
By immunohistochemistry, all the tumors resembled the tumor of
origin and showed a luminal phenotype characterized by the expres-
sion of CK18 and of the neu transgene but not of CK14 (Figure 7B).
These data indicate that the tumor spheres are enriched in tumor-
initiating cells and that the whole sphere condition gives an advan-
tage in respect to single cells in the tumor generation ability.
Tumorigenesis of Sca-1–Positive Cells
Injection of a single sphere derived from Sca-1+ cells displayed a tu-
morigenic ability comparable to that observed in a sphere from the
unsorted tumor population (Sca-1+ cells: 9/12 tumors; unsorted cells:
10/12 tumors). Moreover, we generated sphere clones from Sca-1+ cells
(n = 3), by plating one single Sca-1+ cell per well into 96-well culture
plates in sphere medium. A single sphere from Sca-1+ clones injected
subcutaneously generated tumors similar to those of origin (4/6 tumors).
Finally, Sca-1+ cells were sorted from the entire fresh tumor cell popula-
tion and directly injected in syngeneic mice to evaluate their tumor-
generating ability. As low as 100 Sca-1+ cells were able to generate tumors,
whereas Sca-1–negative cells did not, even using 10,000 cells (Table 2).
Altogether, these data suggest that the Sca-1+ population is the cell
population responsible for sphere generation in culture and for initi-
ating tumors in vivo.
Discussion
In the present study, we showed that tumors driven by the activated
form of the rat Her-2/neu oncogene contain a Sca-1+ population of
sphere-generating cells with the ability to initiate tumors in vivo.
Tumor sphere generation is a useful tool to select a cancer stem cell
population. In our experiments, tumor spheres in culture were shown to
be composed of self-renewing tumor cells with the capacity to express
markers of basal (CK19), luminal (CK18), and myoepithelial (CK14)
differentiative lineages. In contrast, epithelial cells of the tumor only ex-
pressed the luminal type CK18 as the original tumor. These data indi-
cate that cells originated within tumor spheres possess some potential
to differentiate in vitro in the different mammary lineages. Other cancer
stem cell characteristics, also present in the tumor sphere–derived cells,
were the chemoresistance and the tumor-initiating properties. Indeed,
the ability to resist to drugs and to irradiation has been described in tu-
mor stem cells [33–35] and may be of relevance for the design of tu-
mor therapy [36,37]. Altogether, these data indicate that a population
of tumor sphere–generating cells with stem cell properties is present
in the model of the activated neu tumor (BALB-neuTmice). Previous
studies demonstrated the presence of tumor sphere–generating cells in
the model of the unactivated neu proto-oncogene mammary tumors
[18]. Here, we show that the percentage of tumor sphere–generating
cells was elevated in tumors driven by the activated form of neu, in line
with the aggressive development of this tumor.
Different markers have been identified for the selection of mam-
mary stem cells in the normal gland and in the different tumor models.
In mice, CD24+/CD29high cells or CD24+/alpha6+ cells have been de-
scribed as stem cell markers of the normal mammary gland [18,38].
CD24+/CD29high cells have also been shown expanded in preneoplastic
mammary gland of MMTV-Wnt but not MMTV-neu mice. However,
in mice models of MMTV-Wnt1, mammary carcinoma tumor stem
cells were isolated as CD90+(Thy-1)/CD24+ cells [28]. Moreover, in
the p53 null mice, mammary tumor–initiating cells were characterized
by the expression of CD29/CD24 [39]. In the present study, in the
attempt to identify the marker of the stem cell population present
in BALB-neuTmodel, we comparatively evaluated the tumor sphere–
generating ability of CD29-,CD24-, and Sca-1–positive cells. The results
indicate that only the Sca-1 expression identifies the sphere-generating
population in this tumor model, whereas CD29- and CD24-positive
cell populations did not. This finding is different from the observation
by Liu et al. [18] that in tumors generated by the unactivated form
of Her-2/neu, CD24 expression identifies the tumor-initiating popula-
tion independently of Sca-1. In the work by Liu et al. [18], both Sca+/
CD24+ and Sca−/CD24+ cells showed an increase in tumor sphere
generation in vitro and in tumor-generating ability in vivo in respect
to the unsorted population. In our hands, Sca1+ and not Sca1− cells were
enriched of sphere-generating as well as tumor-initiating cells, indepen-
dently of CD24 expression. It is possible that this differential finding
will result from the different model used. Indeed, Her-2 overexpression
may influence the stem cell properties of the tumor cells, as described in
human cells [25].However, as CD24was expressed by the largemajority
Table 1. Tumor-Initiating Ability of Tumor Spheres and Tumor Epithelial Cells.
1 Sphere/2 × 102 Cells 5 Spheres/103 Cells 50 Spheres/104 Cells
Primary passage Spheres 3/6 4/6 6/6
Sphere-derived cells 3/6 6/6 6/6
Tumor epithelial cells 0/6 1/6 6/6
Second passage Spheres 6/8* 6/6 6/6
Tumor epithelial cells 0/6 3/6 6/6
Third passage Spheres 4/4* 4/4 ND
Tumor epithelial cells 0/6 3/6 ND
Whole spheres, spheres disaggregated in single cells (sphere-derived cells), or mature tumor epithelial cells growing in adhesion were subcutaneously injected in the flank of syngeneic BALB/c female, in
an increasing cell number (1, 5, and 50 spheres corresponding approximately to 200, 1000, and 10,000 cells). Tumor generation was evaluated until 3 months. For serial transplant experiments, tumor
spheres and tumor epithelial cells, both obtained from primary tumors, were reinjected to evaluate second tumor generation, and the same procedure was applied for third tumor generation. ND indicates
not done. Differences in tumor incidence between spheres and tumor epithelial cells were evaluated with the χ 2 contingency test in every passage, *P < .01.
Table 2. Tumor-Initiating Ability of Sca1+ Cells.
102 Cells 104 Cells
Sca-1+ cells 3/12 4/4*
Sca-1− cells 0/12 0/6
Sca-1+ cells were sorted from the entire tumor cell population and directly injected in syngeneic
female mice to evaluate their tumor-generating ability. A total of 100 and 10,000 Sca-1–positive and
–negative cells were injected. Tumor generation was evaluated until 3 months. Differences in tumor
incidence were evaluated with the χ 2 contingency test, *P < .05.
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of unsorted tumor cells (>80%), the identification of the CD24 marker
as specific for tumor sphere–generating cells would be in contrast with a
possible increase in sphere-generating and tumor-initiating ability of the
CD24+ in respect to the unsorted population.
The observation that Sca-1+ cells immunomagnetically sorted either
from cultured tumor spheres or from freshly isolated tumor cells displayed
a similar increase in the generation of spheres excludes a culture-due arti-
fact. The tumor sphere culture condition may allow the expansion of this
Sca-1+ population, as the number of these cells in the spheres was signifi-
cantly increased in parallel with the sphere-generating ability of the sec-
ondary spheres.
Sca-1, the first identified mouse stem cell marker, is an anchored
membrane protein expressed by different progenitor populations includ-
ing the mammary gland progenitors. It was primarily discovered in bone
marrow stem cells and then inmost tissues [40]. In themousemammary
tumor models, an overexpression of Sca-1 in MMTV-Wnt tumors
(60%) in respect to MMTV-neu tumors (6-10%) was observed [20].
In the present study, the relevance of Sca-1 expression by the tumor-
initiating cells was supported by experiments of single cell generation
of a tumor sphere from a Sca-1+ cell that in turn was able to generate a
tumor in vivo resembling the tumor of origin. These tumors expressed
CK18, but not CK14 or CK19, indicating a luminal phenotype. In-
deed, the generation in BALB-neuTmice of luminal cell–restricted tu-
mors suggests that Her-2 may expand a population of stem/progenitor
cells already committed to the luminal fate [38]. The role of Her-2 in
the expansion of human breast cancer stem cells has been confirmed in
a recent article, showing that Her-2 overexpression increases the pro-
portion of normal and malignant stem/progenitor cells [25].
Finally, Sca-1–positive cells freshly sorted from the tumor and in-
jected into mice generated tumors with increased growth and incidence
in respect to the tumor epithelial cells and comparable with that of the
tumor sphere–generated cells, indicating their tumor-initiating ability.
In conclusion, we identified a Sca-1+ tumor stem cell population in
BALB-neuTmodel of mammary cancer that strictly resembles the hu-
man breast carcinomas characterized by the Her-2 overexpression. A
large quantity of experimental data shows the possibility of using anti–
Her-2 immunotherapy to prevent the initial stages of tumor growth in
the BALB-neuTmodel [41]. The identification of tumor stem cells in
this model could allow evaluating the effect of immunotherapy also on
this population, which is considered relevant for tumor maintenance.
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